KR102598466B1 - 인플루엔자 바이러스 복제의 억제제로서 유용한 피롤로피리미딘 유도체 - Google Patents

인플루엔자 바이러스 복제의 억제제로서 유용한 피롤로피리미딘 유도체 Download PDF

Info

Publication number
KR102598466B1
KR102598466B1 KR1020197033668A KR20197033668A KR102598466B1 KR 102598466 B1 KR102598466 B1 KR 102598466B1 KR 1020197033668 A KR1020197033668 A KR 1020197033668A KR 20197033668 A KR20197033668 A KR 20197033668A KR 102598466 B1 KR102598466 B1 KR 102598466B1
Authority
KR
South Korea
Prior art keywords
alkyl
delete delete
cycloalkyl
conhch
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197033668A
Other languages
English (en)
Korean (ko)
Other versions
KR20190140971A (ko
Inventor
이리나 씨. 제이콥슨
마이클 데이비드 피세
샘 에스케이. 이
Original Assignee
코크리스탈 파마, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코크리스탈 파마, 아이엔씨. filed Critical 코크리스탈 파마, 아이엔씨.
Publication of KR20190140971A publication Critical patent/KR20190140971A/ko
Application granted granted Critical
Publication of KR102598466B1 publication Critical patent/KR102598466B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020197033668A 2017-04-24 2018-04-24 인플루엔자 바이러스 복제의 억제제로서 유용한 피롤로피리미딘 유도체 Active KR102598466B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762489167P 2017-04-24 2017-04-24
US62/489,167 2017-04-24
PCT/US2018/028986 WO2018200425A1 (en) 2017-04-24 2018-04-24 Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication

Publications (2)

Publication Number Publication Date
KR20190140971A KR20190140971A (ko) 2019-12-20
KR102598466B1 true KR102598466B1 (ko) 2023-11-03

Family

ID=62117141

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197033668A Active KR102598466B1 (ko) 2017-04-24 2018-04-24 인플루엔자 바이러스 복제의 억제제로서 유용한 피롤로피리미딘 유도체

Country Status (21)

Country Link
US (1) US11014941B2 (cg-RX-API-DMAC10.html)
EP (1) EP3615545B1 (cg-RX-API-DMAC10.html)
JP (1) JP7165721B2 (cg-RX-API-DMAC10.html)
KR (1) KR102598466B1 (cg-RX-API-DMAC10.html)
CN (1) CN110637022B (cg-RX-API-DMAC10.html)
AU (1) AU2018257778B2 (cg-RX-API-DMAC10.html)
CA (1) CA3059449A1 (cg-RX-API-DMAC10.html)
DK (1) DK3615545T3 (cg-RX-API-DMAC10.html)
EA (1) EA039181B1 (cg-RX-API-DMAC10.html)
ES (1) ES2901875T3 (cg-RX-API-DMAC10.html)
IL (1) IL269900B (cg-RX-API-DMAC10.html)
MX (1) MX393113B (cg-RX-API-DMAC10.html)
MY (1) MY199746A (cg-RX-API-DMAC10.html)
NZ (1) NZ757442A (cg-RX-API-DMAC10.html)
PH (1) PH12019502376B1 (cg-RX-API-DMAC10.html)
PL (1) PL3615545T3 (cg-RX-API-DMAC10.html)
SG (1) SG11201909478UA (cg-RX-API-DMAC10.html)
SM (1) SMT202100684T1 (cg-RX-API-DMAC10.html)
TW (1) TWI778052B (cg-RX-API-DMAC10.html)
WO (1) WO2018200425A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201906327B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081751A1 (en) * 2018-10-17 2020-04-23 Cocrystal Pharma, Inc. Combinations of inhibitors of influenza virus replication
AU2019380421B2 (en) * 2018-11-13 2025-07-24 Cocrystal Pharma, Inc. Formulations of influenza therapeutics
KR102890026B1 (ko) * 2019-04-26 2025-11-24 닛산 가가쿠 가부시키가이샤 아릴술폰산 에스테르 화합물의 제조 방법
WO2022007966A1 (zh) * 2020-07-10 2022-01-13 四川海思科制药有限公司 Pb2抑制剂及其制备方法和用途
US12559745B2 (en) * 2020-11-23 2026-02-24 The Regents Of The University Of California Methods and compositions for linking RNA stem loops

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148197A1 (en) 2009-06-17 2010-12-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2015073481A1 (en) 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB278965A (en) 1927-03-24 1927-10-20 Gerhard Haar Improved agricultural plough
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4753788A (en) 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
US4946931A (en) 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
AU6909091A (en) 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
CA2379909C (en) 1999-08-06 2011-01-04 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
WO2002013897A2 (en) 2000-08-14 2002-02-21 Advanced Inhalation Research, Inc. Inhalation device and method
CA2433335C (en) 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
CA2456292A1 (en) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Novel virus growth inhibitor and/or virucidal method, and novel pyrazine nucleotide or pirazine nucleoside analog
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
CA2465675C (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
WO2005023335A2 (en) 2003-09-05 2005-03-17 Kurve Technology, Inc. Integrated nebulizer and particle dispersing chamber for delivery of medicament
ES2364340T3 (es) 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
NZ592968A (en) 2006-01-17 2012-08-31 Vertex Pharma Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2
NZ629996A (en) 2012-03-13 2016-10-28 Gilead Sciences Inc 2’- substituted carba-nucleoside analogs for antiviral treatment
SG11201701621YA (en) 2014-09-08 2017-03-30 Janssen Sciences Ireland Uc Pyrrolopyrimidines for use in influenza virus infection
CN105524067A (zh) 2014-09-28 2016-04-27 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
FR3039227B1 (fr) 2015-07-22 2019-12-27 Safran Aircraft Engines Aeronef comprenant un propulseur arriere carene avec stator d’entree a volets mobiles
EP3362451B1 (en) * 2015-12-09 2023-04-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment, amelioration or prevention of influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
CN109071567B (zh) * 2016-05-19 2021-03-23 四川大学 抗流感小分子化合物及其制备方法和用途
DE102017000989A1 (de) * 2017-02-03 2018-08-09 Evonik Degussa Gmbh Verfahren zur Herstellung von Cyclododecanon

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148197A1 (en) 2009-06-17 2010-12-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2015073481A1 (en) 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication

Also Published As

Publication number Publication date
KR20190140971A (ko) 2019-12-20
CN110637022B (zh) 2022-09-16
SG11201909478UA (en) 2019-11-28
MX393113B (es) 2025-03-24
NZ757442A (en) 2022-10-28
ES2901875T3 (es) 2022-03-24
PH12019502376A1 (en) 2020-09-14
WO2018200425A1 (en) 2018-11-01
DK3615545T3 (da) 2021-11-22
EP3615545B1 (en) 2021-09-01
BR112019022307A2 (pt) 2020-05-26
TW201839003A (zh) 2018-11-01
US11014941B2 (en) 2021-05-25
US20200123177A1 (en) 2020-04-23
CN110637022A (zh) 2019-12-31
JP7165721B2 (ja) 2022-11-04
EP3615545A1 (en) 2020-03-04
ZA201906327B (en) 2025-01-29
AU2018257778A1 (en) 2019-10-10
MX2019012759A (es) 2019-12-16
PL3615545T3 (pl) 2022-01-10
EA201992543A1 (ru) 2020-03-24
EA039181B1 (ru) 2021-12-15
TWI778052B (zh) 2022-09-21
SMT202100684T1 (it) 2022-01-10
AU2018257778B2 (en) 2022-02-17
CA3059449A1 (en) 2018-11-01
IL269900B (en) 2022-05-01
JP2020517738A (ja) 2020-06-18
PH12019502376B1 (en) 2024-06-05
MY199746A (en) 2023-11-21

Similar Documents

Publication Publication Date Title
EP3615545B1 (en) Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
EP3849978B1 (en) Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
KR102813547B1 (ko) 인플루엔자바이러스 복제 억제제로서의 피롤로[2,3-b]피리딘 유도체
HK40017162B (en) Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
HK40017162A (en) Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
BR112019022307B1 (pt) Compostos derivados da pirrolopirimidina e uso dos ditos compostos para tratar ou prevenir influenza
JP2023532996A (ja) Fabp4調節化合物の抗ウイルス的使用
HK40017184B (en) Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
HK40017184A (en) Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
HK40046600B (en) Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
HK40046600A (en) Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191114

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210422

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230210

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230828

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231101

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231101

End annual number: 3

Start annual number: 1

PG1601 Publication of registration